BCL2 and B-cell non-Hodgkin lymphoma: With clinical trials on-going and many more being developed using anti-apoptotic BCL-2 family inhibitors for treatment of B cell lymphoma, as well as other hematologic malignancies and solid-organ cancers, there remains a significant lack of knowledge of these proteins and their requirements in non-Hodgkin lymphomas.